Semi-Solid Lipid Matrix for Local Anesthetic Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled release local anesthetic drug products for post-operative pain management suffer from short duration of action, high initial drug burst, inconsistent release kinetics, and systemic side effects, with existing semi-solid formulations being complex, costly, and associated with poor biocompatibility.
Innovation Solution
A semi-solid lipid matrix comprising low solubility triglycerides and modifying excipients, which are fully compatible and miscible, forming a smooth, flowable texture that allows for homogeneous mixing with local anesthetics, providing a biocompatible and bioerodible delivery system with near zero-order release kinetics, reducing initial burst and extending pain relief for up to 72 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If polymeric matrices (poly(DL-lactic acid), poly(lactide-co-glycolide)) are used for controlled release, then drug release is extended to weeks or months, but erosion time is too long for short-term therapy and degradation products cause inflammation
Solution Approach 1:
The patent changes the material parameter from polymeric matrices to semi-solid lipid matrices, fundamentally altering the release mechanism from degradation-based to dissolution-based. This enables shorter, controllable release durations (6-72 hours) without generating inflammatory degradation products, as lipids are metabolized through normal physiological pathways
Solution Approach 2:
The patent employs biocompatible lipids that are rapidly metabolized and eliminated from the body, replacing long-lasting polymeric systems. The lipid matrix provides sufficient duration for post-operative pain management (up to 72 hours) and then naturally dissipates without causing inflammation, effectively using a 'short-living' delivery system matched to the therapeutic need
2Duration of action of moving object
If polyorthoester semi-solid vehicles are used, then controlled release is achieved, but only about 3 wt% drug loading is possible due to low solubility
Solution Approach 1:
The patent changes the chemical parameter of the delivery vehicle from polyorthoester to semi-solid lipid matrix, which fundamentally improves drug solubility and loading capacity. The lipid matrix can accommodate high concentrations of local anesthetics (e.g., bupivacaine, lidocaine, ropivacaine) while maintaining controlled release kinetics, resolving the solubility limitation of polyorthoesters
3Duration of action of moving object
If conventional controlled release systems are used, then extended pain relief is attempted, but initial drug burst and inconsistent release kinetics occur
Solution Approach 1:
The patent utilizes the phase transition properties of semi-solid lipid matrices, which remain stable at physiological temperature and gradually dissolve or melt, providing consistent and predictable drug release. This physical mechanism replaces the unreliable degradation-based release of polymeric systems, eliminating initial bursts and ensuring steady therapeutic levels
Solution Approach 2:
The lipid matrix self-regulates drug release through its inherent dissolution and metabolism characteristics, without requiring complex structural designs or additional controlling mechanisms. The system automatically provides consistent release kinetics based on the lipid's physical properties and the drug's solubility, reducing variability
4Duration of action of moving object
If microencapsulation methods are used, then sustained release is achieved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts the complex microencapsulation manufacturing process and replaces it with a simple mixing and molding process using semi-solid lipid matrices. The active ingredient is directly incorporated into the lipid base without requiring encapsulation in polymeric microspheres or microparticles, dramatically simplifying manufacturing while maintaining sustained release capability
Solution Approach 2:
The patent creates a composite semi-solid formulation combining lipids with local anesthetics, where the lipid matrix itself serves as the delivery vehicle. This eliminates the need for separate encapsulation structures and simplifies the overall system architecture, reducing manufacturing complexity while achieving the desired sustained release effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The semi-solid lipid matrix formulation achieves prolonged and consistent release of local anesthetics, minimizing initial drug burst, enhancing pain relief duration, and reducing systemic side effects, while being easier to manufacture and administer, with improved patient compliance and reduced adverse reactions.
Implementation Method 1
The drug delivery vehicle typically consist of a polymeric matrix from which drug is released by diffusion and/or degradation of the matrix
Implementation Method 2
a biocompatible and bioerodible delivery system with near zero-order release kinetics, reducing initial burst and extending pain relief for up to 72 hours
Implementation Method 3
the erosion time of poly(lactide-co-glycolide) copolymers is measured in weeks to months
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A semi-solid controlled release composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution arsd the methods of manufacturing are disclosed.